U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07071337) titled 'A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy' on June 19.

Brief Summary: The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer who have previously failed endocrine therapy.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Breast Cancer

Intervention: DRUG: SKB264

5mg/kg, IV on Day 1 and Day 15 of each 28 day cycle

DRUG: Nab-p...